Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.08.5431PMID 17158537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.

  2005cited by this paper
• Surgical factors in the treatment of superficial and invasive bladder cancer.

  2005cited by this paper
• Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy.

  2004cited by this paper
• Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer.

  2004cited by this paper
• A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.

  2004cited by this paper
• Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor.

  2004cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

  2004cited by this paper
• Surgical factors influence bladder cancer outcomes: a cooperative group report.

  2004cited by this paper
• A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.

  2004cited by this paper
• Surgical complications of urinary diversion

  2004cited by this paper
• Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

  2004cited by this paper
• 274: Phase II Trial of Intra Vesical Gemcitabine in BCG-Refractory Transitional Cell Carcinoma of the Bladder

  2004cited by this paper
• Bacillus Calmette‐Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression

  2004cited by this paper
• Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study.

  2004cited by this paper
• Local urethral recurrence after radical cystectomy and orthotopic bladder substitution in women: a prospective study.

  2004cited by this paper
• Long-term outcome of ileal conduit diversion.

  2003cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

  2003cited by this paper
• Surgeon volume and operative mortality in the United States.

  2003cited by this paper
• Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.

  2003cited by this paper
• Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study.

  2003cited by this paper
• Late oncological occurrences following radical cystectomy in patients with bladder cancer.

  2003cited by this paper
• Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density.

  2003cited by this paper
• Urinary diversion: ileal conduit to neobladder.

  2003cited by this paper
• Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

  2003cited by this paper
• Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years).

  2003cited by this paper
• Superiority of ratio based lymph node staging for bladder cancer.

  2003cited by this paper
• Adherence to surveillance among patients with superficial bladder cancer.

  2003cited by this paper
• Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions.

  2002cited by this paper
• Long-term complications related to the modified Indiana pouch.

  2002cited by this paper
• Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.

  2002cited by this paper
• [T1 bladder tumors: value of a second endoscopic resection].

  2002cited by this paper
• The remnant urothelium after reconstructive bladder surgery.

  2002cited by this paper
• Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.

  2002cited by this paper
• Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. 1 1 H. Barton Grossman, M.D

  2002cited by this paper
• Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

  2002cited by this paper
• Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

  2002cited by this paper
• A randomized comparative dose‐ranging study of interferon‐α and mitomycin‐C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder

  2002cited by this paper
• Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?

  2002cited by this paper
• Cystectomy for bladder cancer: a contemporary series.

  2001cited by this paper
• Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens.

  2001cited by this paper
• Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy.

  2001cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?

  2001cited by this paper
• Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?

  2001cited by this paper
• Repeated Transurethral Resection and Intravesical BCG for Extensive Superficial Bladder Tumors

  2001cited by this paper
• Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer.

  2001cited by this paper
• Continent urinary reconstruction versus ileal conduit: a contemporary single-institution comparison of perioperative morbidity and mortality.

  2000cited by this paper
• The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.

  2000cited by this paper
• The value of a second transurethral resection in evaluating patients with bladder tumors.

  2000cited by this paper
• Predicting the survival of bladder carcinoma patients treated with radical cystectomy

  2000cited by this paper
• Contemporary management of superficial bladder cancer.

  2000cited by this paper
• Functional lower urinary tract voiding outcomes after cystectomy and orthotopic neobladder.

  2000cited by this paper
• Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

  2000cited by this paper
• Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

  2000cited by this paper
• The orthotopic Kock ileal neobladder: functional results, urodynamic features, complications and survival in 166 men.

  2000cited by this paper
• Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials.

  2000cited by this paper
• Voiding dysfunction in the orthotopic neobladder

  2000cited by this paper
• Recurrence and progression in low grade papillary urothelial tumors.

  1999cited by this paper
• Ileal neobladder and local recurrence of bladder cancer: patterns of failure and impact on function in men.

  1999cited by this paper
• Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.

  1999cited by this paper
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

  1999cited by this paper
• Metabolic consequences of continent urinary diversion.

  1999cited by this paper
• The impact of primary stage on survival in patients with lymph node positive bladder cancer.

  1999cited by this paper
• Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.

  1999cited by this paper
• NEOADJUVANT M-VAC CHEMOTHERAPY OF INVASIVE BLADDER CANCER: RESULTS OF A MULTICENTER PHASE III TRIAL

  1999cited by this paper
• Pelvic lymph node dissection can be curative in patients with node positive bladder cancer.

  1999cited by this paper
• Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure.

  1998cited by this paper
• Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03.

  1998cited by this paper
• Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?

  1998cited by this paper
• Feasibility of radiation and chemotherapy following cystectomy and orthotopic neobladder for invasive bladder cancer.

  1998cited by this paper
• A Randomized Study of Short-v ersus Long-Term Intravesical Epirubicin Instillation for Superficial Bladder Cancer

  1998cited by this paper
• Orthotopic lower urinary tract reconstruction in women using the Kock ileal neobladder: updated experience in 34 patients.

  1997cited by this paper
• High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor.

  1997cited by this paper
• Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome.

  1997cited by this paper
• The Indiana pouch continent urinary reservoir.

  1997cited by this paper
• Orthotopic urinary diversion is a viable option in patients undergoing salvage cystoprostatectomy for recurrent prostate cancer after definitive radiation therapy.

  1997cited by this paper
• Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases.

  1997cited by this paper
• Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup.

  1996cited by this paper
• A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

  1996cited by this paper
• Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1

  1996cited by this paper
• A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. Eortc Genito-Urinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer.

  1996cited by this paper
• A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.

  1996cited by this paper
• The Kock ileal neobladder: updated experience in 295 male patients.

  1996cited by this paper
• Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group.

  1996cited by this paper
• Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.

  1995cited by this paper
• Carcinoma in situ of the bladder.

  1995cited by this paper
• Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study.

  1995cited by this paper
• Original Articles: Bladder Cancer

  1995cited by this paper
• Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder.

  1994cited by this paper
• Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy.

  1994cited by this paper
• Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial.

  1994cited by this paper
• The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results.

  1993cited by this paper
• Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule.

  1993cited by this paper
• The Mitrofanoff principle in urinary reconstruction.

  1993cited by this paper
• Cystectomy and urinary diversion during twenty years--complications and metabolic implications.

  1993cited by this paper
• Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.

  1992cited by this paper
• Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup.

  1992cited by this paper
• Complications of intravesical chemotherapy.

  1992cited by this paper

• The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer

  2025cites this paper
• Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab

  2025cites this paper
• Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update.

  2025cites this paper
• Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer

  2024cites this paper
• Results Obtained from a Pivotal Validation Trial of a Microsatellite Analysis (MSA) Assay for Bladder Cancer Detection through a Statistical Approach Using a Four-Stage Pipeline of Modern Machine Learning Techniques

  2023cites this paper
• Environmental and Occupational Exposures and Prognosis in Patients with Non-Muscle Invasive Bladder Cancer in the Be-Well Study.

  2023cites this paper
• Qualification of the Microsatellite Instability Analysis (MSA) for Bladder Cancer Detection: The Technical Challenges of Concordance Analysis

  2023cites this paper
• The Characteristics of Natural Killer Cells and Prediction of Prognosis in Bladder Urothelial Carcinoma

  2023cites this paper
• PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.

  2023cites this paper
• Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers

  2023cites this paper
• Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for Bladder Cancer Detection

  2023cites this paper
• Improvement of the bladder perfusion curative effect through tight junction protein degradation induced by magnetic temperature-sensitive hydrogels

  2022cites this paper
• Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy

  2022cites this paper
• Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal/squamous-subtype muscle-invasive bladder cancer.

  2022cites this paper
• A systematic review and meta-analysis of radical cystectomy in the treatment of muscular invasive bladder cancer (MIBC)

  2021cites this paper
• Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions

  2021cites this paper
• Role of blue‐light cystoscopy in detecting invasive bladder tumours: data from a multi‐institutional registry

  2021cites this paper
• Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer

  2020cites this paper
• Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo

  2020cites this paper
• PET/CT Imaging with an 18F-Labeled Galactodendritic Unit in a Galectin-1–Overexpressing Orthotopic Bladder Cancer Model

  2020cites this paper
• Flaccidoxide-13-Acetate-Induced Apoptosis in Human Bladder Cancer Cells is through Activation of p38/JNK, Mitochondrial Dysfunction, and Endoplasmic Reticulum Stress Regulated Pathway

  2019cites this paper
• Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma.

  2019cites this paper
• Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor‐β‐induced expression in urothelial carcinoma

  2018cites this paper
• Cell Cycle Markers in the Evaluation of Bladder Cancer

  2018cites this paper
• Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.

  2018cites this paper
• Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

  2018cites this paper
• Overexpression of high mobility group box 1 contributes to progressive clinicopathological features and poor prognosis of human bladder urothelial carcinoma

  2018cites this paper
• Overexpression of high mobility group box 1 contributes to progressive clinicopathological features and poor prognosis of human bladder urothelial carcinoma

  2018cites this paper
• Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

  2018cites this paper
• The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway

  2017cites this paper
• The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era

  2017cites this paper
• In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma

  2017cites this paper
• Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis

  2017cites this paper
• Optical redox ratio and endogenous porphyrins in the detection of urinary bladder cancer: A patient biopsy analysis

  2017cites this paper
• The SMAD2/3 pathway is involved in hepaCAM-induced apoptosis by inhibiting the nuclear translocation of SMAD2/3 in bladder cancer cells

  2016cites this paper
• SnoN suppresses TGF-β-induced epithelial-mesenchymal transition and invasion of bladder cancer in a TIF1γ-dependent manner.

  2016cites this paper
• Dual tumor‐suppressors miR‐139‐5p and miR‐139‐3p targeting matrix metalloprotease 11 in bladder cancer

  2016cites this paper
• Stage T1 Bladder Cancer – Aspects of Diagnosis and Treatment

  2016cites this paper
• Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy.

  2016cites this paper
• A new drug delivery system for Mitomycin C to improve intravesical instillation

  2016cites this paper
• Stage T 1 Bladder Cancer – Aspects of Diagnosis and Treatment

  2016cites this paper
• Development of non-invasive techniques for bladder cancer diagnosis and therapy

  2016cites this paper
• Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model

  2016cites this paper
• Impact of chemotherapeutics drugs in NK-mediated killing by over expression of death receptors on cancer cells

  2015cites this paper
• Comparative Study of 2um Laser versus Ho lmium Laser for the Resectionof Non-Muscle Invasive Bladder Cancer

  2015cites this paper
• Depth of Invasion in High-Grade T1 Bladder Cancer: Added Value In Timely Cystectomy?

  2015cites this paper
• Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway

  2015cites this paper
• The expression of AEG-1 and Cyclin D1 in human bladder urothelial carcinoma and their clinicopathological significance.

  2015cites this paper
• Different patterns in the prognostic value of age for bladder cancer-specific survival depending on tumor stages.

  2015cites this paper
• The Role of Genomics in the Management of Advanced Bladder Cancer

  2015cites this paper
• Interaction network analysis of differentially expressed genes and screening of cancer marker in the urine of patients with invasive bladder cancer.

  2015cites this paper
• Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.

  2014cites this paper
• α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.

  2014cites this paper
• Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence.

  2014cites this paper
• Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.

  2014cites this paper
• Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder

  2014cites this paper
• Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway

  2014cites this paper
• Phosphorylated p70S6K in noninvasive low-grade urothelial carcinoma of the bladder: correlation with tumor recurrence

  2014cites this paper
• High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids

  2014cites this paper
• Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo

  2014cites this paper
• Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial-mesenchymal transition and activation of Akt/GSK-3β/Snail signaling.

  2013cites this paper
• Molecular targets on the horizon for kidney and urothelial cancer

  2013cites this paper
• Alterations of histone H1 phosphorylation during bladder carcinogenesis.

  2013cites this paper
• Cytologic and cystoscopic predictors of recurrence and progression in patients with low‐grade urothelial carcinoma

  2013cites this paper
• Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: A preliminary investigation

  2013cites this paper
• Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression

  2013cites this paper
• Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.

  2013cites this paper
• Clinicopathological Analysis of Patients with Nonmuscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy

  2012cites this paper
• The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway.

  2012cites this paper
• Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells

  2012cites this paper
• The tumor-suppressor gene Nkx 2 . 8 suppresses bladder cancer proliferation through upregulation of FOXO 3 a and inhibition of the MEK / ERK signaling pathway

  2012cites this paper
• Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.

  2011cites this paper
• Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.

  2011cites this paper
• Early vs delayed radical cystectomy for ‘high‐risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer‐specific survival

  2011cites this paper
• Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin

  2010cites this paper
• Combined-Modality Treatment for High Risk TCC of the Bladder

  2010cites this paper
• Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

  2010cites this paper
• Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice

  2010cites this paper
• Molecular screening for bladder cancer: progress and potential

  2010cites this paper
• Association of Selected Variants in Genes Involved in Cell Cycle and Apoptosis with Bladder Cancer Risk in North Indian Population

  2010cites this paper
• Effects of Simultaneous Transurethral Resection of Non-Muscle-Invasive Bladder Cancer and Benign Prostatic Hyperplasia

  2009cites this paper
• Suprapubic mass in patient with neurogenic bladder due to spinal cord injury managed with indwelling suprapubic tube.

  2009cites this paper
• Somatic mutations of adenomatous polyposis coli gene and nuclear b‐catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication

  2009cites this paper
• Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.

  2009cites this paper
• Current trends in the management of bladder cancer.

  2009cites this paper
• Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer.

  2009cites this paper
• Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer.

  2009cites this paper
• Current status of prostate-sparing cystectomy.

  2008influential citation
• Development of a Multiplex RNA Urine Test for the Detection and Stratification of Transitional Cell Carcinoma of the Bladder

  2008cites this paper
• Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF

  2008cites this paper
• Prognostic significance of altered p120ctn expression in bladder cancer

  2008cites this paper
• -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro.

  2008cites this paper
• Development of a Multiplex RNAUrine Test for the Detection and Stratification ofTransitional Cell Carcinoma of the Bladder

  2008cites this paper
• Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties

  2008cites this paper
• Bladder tumor markers: from hematuria to molecular diagnostics – where do we stand?

  2008cites this paper
• Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival

  2008cites this paper
• Seminar article Current status of prostate-sparing cystectomy

  2008cites this paper
• Urothelial carcinomas of the urinary tract : molecular analyses for clinical applications

  2007cites this paper
• Prostate-sparing cystectomy: has Pandora’s box been opened?

  2007cites this paper
• Conditional survival in head and neck squamous cell carcinoma

  2007cites this paper